Beach TG, Potter PE, Sue LI, Fisher A, Scott S, Layne KJ, Newell AJ, Roher AE, Walker DG (2002) Cerebral abeta deposition induced by cortical cholinergic deafferentation is reduced by cholinergic therapy. Neuroscience 2002 Abstracts 722.9. Society for Neuroscience, Orlando, FL.
Summary: We have previously shown that cortical cholinergic deafferentation in rabbits results in cerebral Abeta deposition (Neurosci Lett 283:9-12, 2000). We have also shown that cholinergic therapy with acetylcholinesterase inhibitors and muscarinic agonists reduces Abeta concentrations in the CSF and cortex of normal rabbits (Neurosci Lett 310:21-24, 2001; Brain Res 905:220-223, 2001). Here we show that the histologic deposition and biochemical elevations of Abeta induced by cholinergic immunotoxin are reduced by systemic therapy with AF267B, an M1-selective muscarinic agonist, and physostigmine, an acetylcholinesterase inhibitor. Rabbits received i.c.v. injections of an immunotoxin composed of the p75 NTR-directed monoclonal antibody ME20.4 conjugated to saporin, a ribosomal toxin. One group of animals received s.c. AF267B (2 mg/kg/day) while another group received s.c. physostigmine (3 mg/kg/day). Control groups received either i.c.v. immunotoxin or sham lesion (i.c.v. saline) and no treatment. Four weeks after surgery, imunohistochemical staining for Abeta showed frequent positive blood vessels and perivascular diffuse plaques in the control group which received immunotoxin injection and no treatment. This was significantly reduced in animals which received either AF267B or physostigmine. Cerebrospinal fluid Abeta concentrations were also reduced significantly by both drug treatments. These results are directly relevant to humans since cortical cholinergic deafferentation is part of normal human aging.
Related Products: ME20.4-SAP (Cat. #IT-15)